DCGI APPROVES MERCK'S ERBITUX FOR TREATMENT OF HEAD & NECK CANCER IN INDIA

Merck Specialities has received marketing approval for Erbitux, its gold standard new-targeted cancer therapy drug, for the treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) cancer. Erbitux is the first and only monoclonal antibody to be approved for the treatment of head and neck cancer by the US FDA and the EMEA. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=35426ionid=)